Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-01-17 | recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) | CSL Behring (USA) | hemophilia A and hemophilia B patients with inhibitors | |
2012-03-15 | Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD) | GW Pharmaceuticals (UK) Almirall (Spain) | spasticity due to multiple sclerosis |
Granting of a patent |
2012-03-30 | Aclidinium bromide | Almirall (Spain) Forest Laboratories (USA) | chronic obstructive pulmonary disease (COPD) | |
2017-01-26 | linaclotide | Almirall (Spain) Allergan (Ireland) |
|
Granting of a Market Authorisation in the US |
2018-01-25 | TK cell therapy | MolMed (Italy) |
|
Product launch |
2011-02-07 | MOR103 | Morphosys (Germany) | Granting of a patent | |
2012-01-13 | T1 technology | ORCA Therapeutics (The Netherlands) | cancer | |
2012-01-15 | PLX cells | Pluristem Therapeutics (Israel) | thromboangiitis obliterans (Buerger\'s disease) | |
2012-01-18 | EV-077 | Evolva (Switzerland) | complications of diabetes (including loss of kidney function and increased risk of thrombosis). |
Granting of a patent |
2012-01-28 | glucarpidase injection | BTG International (UK) | treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. | |
2012-04-27 | AMEP™ (targeted biotherapy) | BioAlliance Pharma (France) | metastatic melanoma |
Granting of a patent |
2012-01-25 | AFC-5128 | Affectis Pharmaceuticals (Germany) | neuropathic pain multiple sclerosis |
|
2018-10-18 | ivacaftor | Vertex Pharmaceuticals (USA - MA) |
|
Positive opinion for the granting of a Market Authorisation in the EU |
2012-02-02 | talactoferrin | Agennix (Germany) | malignant neoplasms and other hyperproliferative diseases
|
|
2012-02-08 | NRP-1 small molecule antagonists | Ark Therapeutics (UK) | cancers | |
2012-02-08 | pertuzumab | Genentech, a member of the Roche Group (USA - Switzerland) |
|
Granting of a Market Authorisation in the EU |
2012-04-30 | Meningococcal group A, C, W135 and Y conjugate vaccine | GSK Biologicals (UK) | active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135 and Y |
Granting of a Market Authorisation in the EU |
2012-02-17 | granisetron | ProStrakan (UK) | prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult. |
|
2013-10-21 | tocilizumab | Chugai (Japan) Roche (Switzerland) Genentech (USA) |
|
Granting of a Market Authorisation in the US |
2012-02-29 | GLPG0778 and its back-up compound GLPG0555 |
© 2024 Biopharmanalyses - Powered by Samacom+